Authors
Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa
Published in
Current treatment options in oncology. Volume 27. Issue 1. Oct 28, 2026. Epub Oct 28, 2026.
Abstract
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) has established a new curative-intent standard for resectable gastric and gastroesophageal junction adenocarcinoma. Recurrence after this regimen creates a clinically distinct, pre-exposed metastatic state for which no prospective sequencing standard exists. Because direct post-D-FLOT evidence is absent, treatment decisions should distinguish exposure-analogous evidence from extrapolation from conventional metastatic trials. In practice, we first determine whether recurrence after perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is potentially amenable to local treatment and, if systemic therapy is required, document the recurrence phase, the dates of the last FLOT and durvalumab doses, prior radiographic and pathological response, residual neuropathy, immune-related adverse events, organ function, performance status, and disease tempo. We then obtain recurrent-tumor tissue when feasible and reassess human epidermal growth factor receptor 2 (HER2), claudin 18.2 (CLDN18.2), and microsatellite instability/mismatch repair status; programmed death-ligand 1 results are interpreted in the context of assay differences and prior durvalumab exposure. If HER2 is positive and no prior HER2-directed therapy was given, we prioritize a HER2-directed strategy. If CLDN18.2 is positive and HER2 negative, zolbetuximab-based therapy is reasonable when oxaliplatin re-use is clinically defensible, but very early relapse or persistent neuropathy should favor an alternative strategy or a clinical trial. Microsatellite instability-high or mismatch repair-deficient disease remains immunologically compelling, although checkpoint-inhibitor re-use after durvalumab is not established. In biomarker-negative disease recurring during treatment or within about 6 months, we favor a non-cross-resistant approach, using ramucirumab- or irinotecan-based therapy according to prior taxane exposure, neuropathy, and regional availability. With a longer treatment-free interval and recovered toxicity, selective fluoropyrimidine/platinum reintroduction becomes more reasonable. We avoid routine checkpoint-inhibitor rechallenge solely because programmed death-ligand 1 is positive. For trial eligibility and line-of-therapy nomenclature, we count recurrence within 12 months of the last administered perioperative systemic dose (chemotherapy or durvalumab, whichever was later) as one prior systemic line, while recognizing that this is a pragmatic classification rather than a validated biologic cutoff.
PMID:
42955495
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0